Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Completed · Phase 4

Conditions studied: Hypertension, Left Ventricular Hypertrophy

In brief

Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.

Key facts

Study ID

NCT00139555

Run by

Novartis

People needed

125

Starts

2004-07-01

Expected to finish

2006-11-01

Last updated by the study team

2017-02-23

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or female patients ≥ 55 years of age
• LVH as confirmed by echocardiogram
• Patients with high risk hypertension, currently treated or already taking antihypertensive medication

You may not qualify if…

• Renal artery stenosis
• Symptomatic heart failure or known ejection fraction < 40%
• Myocardial infarction or stroke within 6 months
• Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers
• Pregnant or lactating females
• Cancer within the last 5 years

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.